

Publications ATIR101

Publications (full text & abstracts)

2017

Bönig H, Velthuis J, Walker I et al. Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT. Cytotherapy (ISCT Annual Meeting Abstracts).2017 (Abstract)

Rovers J, Janssen S, Gerez L et al. Introduction of the HATCHY study: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101 with post- transplant cyclophosphamide in patients with a hematologic malignancies Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2017 (Abstract) (Poster)

Corbacioglu S, Wynn R, Lawson S et al. An exploratory, open- label study to evaluate the safety and feasibility of ATIR201, a T- lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T- cells (using photodynamic treatment), as adjuvant treatment to a T- cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta- thalassemia major Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2017 (Abstract) (Poster)

2016

Roy DC, Lachance S, Roy J et al. Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. Blood (ASH Annual Meeting Abstracts).2016 (Abstract)

Roy DC, Lachance S, Roy J et al. Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL. Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2016;51 (*Abstract*)

Mielke S, Maertens J, Selleslag D et al. Effect of graft on safety and efficacy in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2016;51 (*Abstract*)(*Poster*)

Velthuis J, Klar R, Bonig H et al. Leukemia-associated antigen reactive T-cells in ATIR101, a recipient-specific allodepleted T-cell product facilitating haploidentical HSCT. Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2016;51 (*Abstract*)(*Poster*)

Mielke S, Roy DC, Freudenthal R et al. An exploratory, open-label, multicenter study to evaluate safety and efficacy of a two-dose regimen of ATIR in patients with a hematologic malignancy, who receive a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor. Bone Marrow Transplant. (EBMT Annual Meeting Abstracts).2016;51 (*Abstract*)(*Poster*)

2015

Roy DC, Lachance S, Roy J, Walker I et al. Donor lymphocytes depleted of alloreactive T-cells (ATIR101) reduce transplant related mortality and improve overall survival in haploidentical



Publications ATIR101

HSCT for patients with AML and ALL, using an immunosuppressant-free transplant regimen. [abstract]. Blood (ASH Annual Meeting Abstracts).2015;126 (*Meeting Abstract*)

2014

Velthuis J, de Jong LA, Boumedine RS et al. Selective depletion of recipient-alloreactive T- cells while retaining viral-specific and memory T-cells enables safe and efficacious haplo- identical HSCT [abstract]. Blood (ASH Annual Meeting Abstracts). 2014;124 (*Meeting Abstract*)

Velthuis J, de Jong LA, Boumedine RS et al. Selective depletion of recipient-alloreactive T- cells while retaining viral-specific and memory T-cells enables safe and efficacious haplo- identical HSCT [abstract]. Bone Marrow Transplant (EBMT Annual Meeting). 2014;49:S127- S128

Roy DC, Maertens J, Walker I et al. Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS [abstract]. Blood (ASH Annual Meeting Abstracts). 2014;124 (*Meeting Abstract*)

Roy DC, Maertens J, Walker I et al. Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS [abstract]. Bone Marrow Transplant (EBMT Annual Meeting). 2014;49

2013

Gerez L, Ruediger M, Roy D. Stem cell transplantation from haplo-identical donors. Pharma Bio World 11[12], 34-38. 2013 (*Link*)

2012

Bastien JP, Roy J, Roy DC. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol. 2012;39:674-682 (*PubMed*)

Perruccio K, Topini F, Carotti A et al. Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. Bone Marrow Transplant. 2012;47:1196-1200 (*PubMed*)

2011

Roy DC, Guerin M, Boumedine RS et al. Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units. ASH Annual Meeting Abstracts. 2011;118:3020 (*Meeting Abstract*)

Mielke S, McIver ZA, Shenoy A et al. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2011;17:1855-1861 (*PubMed*)

2010

Bastien JP, Krosl G, Therien C et al. Novel Photodepletion Strategy to Preserve and Expand



Publications ATIR101

Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116 (*Meeting Abstract*)

Bastien JP, Krosl G, Therien C et al. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood. 2010;116:4859-4869 (*PubMed*)

2009

Roy DC, Lachance S, Kiss T et al. Haploidentical Stem Cell Transplantation: High Doses of Alloreactive T-Cell Depleted Donor Lymphocytes Administered Post-Transplant Decrease Infections and Improve Survival without Causing Severe GvHD. ASH Annual Meeting Abstracts. 2009;114:512 (*Meeting Abstract*)

Roy D, Lachance S, Kiss T et al. Alloreactive T-cell depleted donor lymphocyte infusions decrease infections without causing severe GvHD after haplotype mismatched stem cell transplantation. Bone Marrow Transplant. 2009;43:S2 (*Meeting Abstract*)

Mielke S, Shenoy A, Rezvani K et al. Allografts Selectively Photodepleted of GvHD Causing T Cells and Followed by Low-Level Immunosuppression: A Novel Method to Improve Disease Control After HLA-Matched Sibling Transplantations [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114:515 (*Meeting Abstract*)

2008

Perruccio K, Topini F, Tosti A et al. Adoptive immunotherapy after haploidentical stem cell transplantation with T-cells allodepleted by photodynamic purging. Bone Marrow Transplant (EBMT Annual Meeting). 2008;41:S24-S25

Perruccio K, Topini F, Tosti A et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis. 2008;40:76-83 (*PubMed*)

Perruccio K, Topini F, Tosti A et al. Adoptive Immunotherapy after Haploidentical Stem Cell Transplantation with T Cells Allodepleted by Photodynamic Purging [abstract]. Blood. 2008;112:1157 (*Meeting Abstract*)

Mielke S, Shenoy A, Fellowes VS et al. Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies. ASH Annual Meeting Abstracts. 2008;112:1168 (*Meeting Abstract*)

Mielke S, Shenoy A, Fellowes VS et al. First Clinical report of matched sublings allografts for haematological malignancies using selectively photodepleted T-cells and purified peripheral blood stem cells [abstract]. Bone Marrow Transplant (EBMT Annual Meeting). 2008;41:S329-



Publications ATIR101

S330

2007

Roy DC, Cohen S, Busque L et al. Phase I Clinical Trial of Haplotype Mismatched Myeloablative Stem Cell Transplantation: Higher Doses of Donor Lymphocyte Infusions Depleted of Alloreactive Cells Using ATIR May Improve Outcome without Causing GVHD [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:2976 (*Meeting Abstract*)

Roy D, Cohen S, Busque L et al. Escalated-dose donor lymphocyte infusion depletion of alloreactive T-cells may limit infections and malignant relapse without causing GvHD after haplotype mismatched myeloablative stem cell transplantation. Bone Marrow Transplant. 2007;39:S105 (*Meeting Abstract*)

Mielke S, Nunes R, Rezvani K et al. Successful Translation of a GMP-Based, Clinical Scale Selective Allodepletion Approach for Matched Donor-Recipient Pairs from Bench-to-Bedside [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:3279 (*Meeting Abstract*)

Perruccio K, Topini F, Tosti A et al. Photodynamic purging of alloreactive T-cells for adoptive immunotherapy after haplo-identical stem cell transplantation [abstract]. Bone Marrow Transplant. 2007;39:S221-S222

2006

Roy DC, Cohen S, Busque L et al. Phase I Clinical Study of Donor Lymphocyte Infusion Depleted of Alloreactive T Cells after Haplotype Mismatched Myeloablative Stem Cell Transplantation To Limit Infections and Malignant Relapse without Causing GVHD [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108:309 (*Meeting Abstract*)

Mielke S, Nunes R, Rezvani K et al. High Efficiency Clinical Scale Selective Depletion of Alloreacting T Cells Using Expanded T Lymphocytes as Antigen-Presenting Cells and a TH9402-Based Photodepletion Technique in HLA-Mismatched and Matched Donor-Recipient Pairs [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108:721 (*Meeting Abstract*)

2005

Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7:109-115 (*PubMed*)

Levesque A, Savard AL, Roy DC, Foss F, and Scotto C. Control of Cell Death Levels Using Th9402-Based PDT Treatment on Fresh PBMC, and Potential Application to Patients with cGvHD [abstract]. Blood (ASH Annual Meeting Abstracts). 2005;106:5258 (*Meeting Abstract*)



Publications ATIR101

Boumedine RS, Roy DC. Elimination of alloreactive T cells using photodynamic therapy. Cytotherapy. 2005;7:134-143 (*PubMed*)

2004

Levesque A, Savard AL, Roy DC, Foss F, and Scotto C. Potential TH9402-Based ECP Treatment for cGvHD Patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2004;104:5119 (*Meeting Abstract*)

Krosl G, Dube P, Dallaire N, Vaillancourt M, and Roy DC. Preferential Induction of B Cell Apoptosis Using Photodynamic Therapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2004;104:4643 (*Meeting Abstract*)

Boumedine RS, Krosl G, Vaillancourt M, Perreault C, and Roy DC. Specific Elimination of Alloreactive T Lymphocytes Using Photodynamic Therapy Prevents GVHD and Enables Rapid Immune Reconstitution [abstract]. Blood (ASH Annual Meeting Abstracts). 2004;104:4987 (*Meeting Abstract*)

2002

Anasetti C. Photodynamic purging of immunoreactive T cells: the magic bullet? Blood. 2002;99:3081 (*PubMed*)

Terra R, Balassy A, Barrette M, Rooney J, and Roy D. Specific Elimination of Alloreactive T Lymphocytes by TH9402 based Photodynamic Therapy [abstract]. Experimental Hematology. 2002;30:119 (*PubMed*)

Roy D, Guimond M, Balassy A et al. Selective elimination of immunoreactive T cells using a unique strategy to target P-glycoprotein [abstract]. ISEH 2002. (*PubMed*)

Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood. 2002;99:3083-3088 (*PubMed*)

Guimond M, Balassy A, Barrette M et al. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood. 2002;100:375-382 (*PubMed*)

2001

Chen BJ, Cui X, and Chao NJ. Prevention of GVHD While Preserving GVL Effect and Anti-Third Party responses after Selective Depletion of Host-Reactive T Cells by Photodynamic Cell Purging Process [abstract]. Blood (ASH Annual Meeting Abstracts). 2001.

2000

Guimond M, Brochu S, Perreault C, Molfino N, and Roy DC. Specific elimination of anti-host alloreactivity using a photodynamic approach [abstract]. FASEB J. 2000;14:A1074



Publications ATIR101

1999

Villeneuve L. *Ex vivo* photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem. 1999;30 (Pt 1):1-17 (*PubMed*)

Roy DC, Paquette Y, Balassy A et al. Elimination of Chronic Myleoid Leukemia (CML) Cells With a Novel Photodynamic Treatment [abstract]. Blood. 1999;94:144a

1996

Pal P, Zeng H, Durocher G et al. Phototoxicity of some bromine-substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers. Photochem Photobiol. 1996;63:161-168 (*PubMed*)

Villeneuve L, Pal P, Durocher G et al. Spectroscopic and photophysical investigations on the nature of localization of rhodamine-123 and its dibromo derivative in different cell lines. Journal of fluorescence. 1996;6:209-219 (*PubMed*)